While immunotherapies, such as programmed cell death protein 1 (PD-1) checkpoint inhibitors that improve anti-tumor immune responses, have revolutionized melanoma treatment [14], the disease remains responsible for over fifty thousand deaths annually, with incidence and mortality rates rising worldwide [15,16]. The gene discussed is PDCD1; the disease is melanoma.